Contrast medium Pd/Pa ratio in comparison to fractional flow reserve, quantitative flow ratio and instantaneous wave-free ratio for evaluation of intermediate coronary lesions

Paweł Kleczyński¹, Artur Dziewierz², Łukasz Rzeszutko², Dariusz Dudek², Jacek Legutko¹

¹Department of Interventional Cardiology, John Paul II Hospital, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland ²2nd Department of Cardiology, University Hospital, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

> Adv Interv Cardiol 2020; 16, 4 (62): 384–390 DOI: https://doi.org/10.5114/aic.2020.101762

Abstract

Introduction: Contrast medium Pd/Pa ratio (cFFR) was introduced as an alternative to fractional flow reserve (FFR).
 Aim: To assess the accuracy of cFFR in predicting of FFR, quantitative flow ratio (QFR) and instantaneous wave-free ratio (iFR).
 Material and methods: Resting Pd/Pa, cFFR, FFR, QFR, and iFR were measured in 110 intermediate coronary lesions. cFFR was obtained after intracoronary injection of contrast medium. FFR was measured after the intravenous administration of adenosine.
 QFR was derived from fixed empiric hyperemic flow velocity based on coronary angiography. iFR was calculated by measuring the resting pressure gradient across a coronary lesion during diastole.

Results: Forty-four patients with 110 intermediate coronary lesions were enrolled. Mean baseline Pd/Pa was 0.93 ±0.05. Mean cFFR value was similar to FFR value (0.83 ±0.09 vs. 0.81 ±0.09; p = 0.13) and QFR (0.81 ±0.1; p = 0.69) and iFR (0.90 ±0.07; p = 0.1). A total of 46 vessels (41.8%) had FFR \leq 0.80, 50 (45.5%) vessels had cFFR \leq 0.83, 44 (40.0%) vessels had QFR \leq 0.80, and 38 (34.5%) vessels had iFR \leq 0.89. An excellent agreement between cFFR and resting Pd/Pa, FFR, QFR, and iFR was confirmed (intraclass correlation coefficients of 0.83, 0.99, 0.98, and 0.88, respectively). The optimal cutoff value of cFFR was 0.83 for prediction of FFR \leq 0.80 with sensitivity, specificity, and accuracy of 96.9%, 97.8%, and 97.3%, respectively. 100% sensitivity was observed for a cutoff value of 0.82 and 100% specificity for a cutoff value of 0.84; AUC = 0.998 (0.995–1.00); p < 0.001.

Conclusions: Contrast medium Pd/Pa ratio seems to be accurate in predicting the functional significance of borderline coronary lesions assessed with FFR, iFR, and QFR.

Key words: coronary artery disease, fractional flow reserve, quantitative flow ratio, instantaneous wave free ratio, Pd/Pa.

Summary

Resting Pd/Pa, contrast medium Pd/Pa ratio (cFFR), fractional flow reserve (FFR), quantitative flow ratio (QFR), and instantaneous wave-free ratio (iFR) were measured in 110 intermediate coronary lesions. Mean baseline Pd/Pa was 0.93 ±0.05. Mean cFFR value was similar to FFR value (0.83 ±0.09 vs. 0.81 ±0.09; p = 0.13) and QFR (0.81 ±0.1; p = 0.69) and iFR (0.90 ±0.07; p = 0.1). A total of 46 (41.8%) vessels had FFR \leq 0.80, 50 (45.5%) vessels had cFFR \leq 0.83, 44 (40.0%) vessels had QFR \leq 0.80, and 38 (34.5%) vessels had iFR \leq 0.89. An excellent agreement between cFFR and resting Pd/Pa, FFR, QFR, and iFR was confirmed (intraclass correlation coefficients of 0.83, 0.99, 0.98, and 0.88, respectively). The optimal cutoff value of cFFR was 0.83 for prediction of FFR \leq 0.80 with sensitivity, specificity, and accuracy of 96.9%, 97.8%, and 97.3%, respectively. 100% sensitivity was observed for a cutoff value of 0.82 and 100% specificity for a cutoff value of 0.84; AUC = 0.998 (0.995-1.00); p < 0.001.

Introduction

Fractional flow reserve (FFR) obtained after the achievement of pharmacologically induced maximal

hyperemia has been demonstrated not only as a gold standard for the assessment for intermediate coronary stenosis severity in the cathlab but also as a parameter improving prognosis in terms of revascularization with

Corresponding author:

Paweł Kleczyński MD, PhD, Department of Interventional Cardiology, John Paul II Hospital, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland, phone: +48 12 424 71 81, e-mail: kleczu@interia.pl **Received:** 30.08.2020, **accepted:** 1.10.2020. a fixed cut-off value of 0.8 [1-6]. Recent data confirmed the non-inferiority of instantaneous wave-free ratio (iFR) to FFR in terms of lesion severity assessment along with long-term clinical outcomes [7, 8]. Quantitative flow ratio (QFR) assessment, on the other hand, involves an advanced algorithm that enables fast computation of pressure decreases in intermediate coronary artery disease (CAD) without any invasive physiologic measurements or pharmacologic hyperemia induction, and its diagnostic performance has already been confirmed [9, 10]. Radiographic contrast medium, routinely used during coronary angiography, has been demonstrated to induce hyperemia, e.g. during the check of pressure wire placement [11]. Pd/Pa ratio registered by pressure wire during submaximal reactive hyperemia induced by intracoronary injection of contrast medium may be sufficient for the assessment of the physiological severity of stenosis in a large number of cases, avoiding the need of adenosine administration. The CONTRAST study, comparing the ability of contrast medium Pd/Pa ratio (cFFR) to predict FFR versus resting indices, showed that cFFR was superior to resting Pd/Pa and iFR for predicting FFR while resting Pd/Pa and iFR provided equivalent diagnostic accuracy [12]. Several studies showed a good correlation of cFFR with FFR [13, 14].

Aim

In our study, we sought to investigate the performance strength of cFFR against FFR, iFR, and a novel tool, QFR, as a comprehensive assessment of intermediate CAD.

Material and methods

Patients with stable CAD with angiographically ambiguous lesions (40–90% diameter stenosis by visual assessment) in a major epicardial coronary artery, who were scheduled for FFR, were prospectively and consecutively enrolled. Baseline clinical data were collected. Ethics approval was granted from the institutional ethics review process and all patients gave written informed consent.

Study protocol

Coronary angiography was performed with the standard femoral or radial approach based on individual operator preferences. The acquisition was done at 15 fps for the best image quality. The s5/s5i console and Verrata Pressure Guide Wire (Philips Volcano Corporation, San Diego, California) were used in all cases. Data acquisition included an electrocardiographic signal recording. Firstly, the pressure wire was advanced distally to the index lesion. After confirmation of wire position and waiting until the return of Pd/Pa ratio to the baseline value, cFFR was assessed in the following pattern. A single rapid manual injection of 3 ml of radiographic contrast medium through a contrast dye filled guiding catheter (+ 2 ml additional volume of contrast dye) (Visipaque 320, GE Healthcare, USA) was performed and the minimal cFFR value obtained was recorded (in general within the first 10 s). Each injection of contrast medium was duplicated to test the reproducibility of cFFR. After any injection of contrast medium, flushing of the guiding catheter with saline was performed to avoid pressure damping due to contrast medium viscosity. The pressure wire was pulled back to the left main or ascending aorta to check for potential pressure drift. Afterwards, the wire was advanced once again distally to the evaluated lesion and after its position check, saline flush of the guiding catheter and another 60 s of wait, iFR was calculated using fully automated algorithms in a typical way [15]. After iFR assessment, we started adenosine administration through a femoral vein at a rate of 140 [µg/kg/min] for a minimum of 3 min. The detailed, meticulous methodology of the FFR/iFR procedure was previously described [16–18]. The pressure wire pullback maneuver was mandatory to check for pressure drift. Computation of QFR was performed offline, using a software package (Medis Suite 2.1.12.2, Medis Medical Imaging System, Leiden, the Netherlands) by an independent corelab analyzer blinded to iFR, FFR, and cFFR results [10, 19]. The analysis was conducted twice by each analyzer and the mean value (from four calculations) was used for further analysis. The intra- and inter-observer variability were determined using the intraclass correlation coefficient (ICC). The limited intra- and interobserver variability for measuring the QFR was confirmed by ICC of 0.991 (95% CI: 0.988-0.993) and 0.990 (95% CI: 0.987-0.992), respectively.

Quantitative coronary angiography (QCA) was performed by an independent corelab analyzer blinded to the results of FFR, using the edge detection system (CAAS 5.7 QCA system, Pie Medical).

Statistical analysis

Categorical variables were expressed as numbers of patients (percentages). Continuous variables were expressed as mean \pm standard deviation (SD). Non-normally distributed data were reported as median (interquartile range (IQR)). The agreement among tested methods was assessed by the Bland-Altman plot method and ICC. Data are presented as the unadjusted area under the ROC curve (AUC) with 95% CI. All tests were 2-tailed, and a *p*-value < 0.05 was considered statistically significant. All statistical analyses were performed using Statistica 13.3 (TIBCO Software Inc., Palo Alto, CA, USA).

Results

Forty-four patients with 110 intermediate coronary stenoses were enrolled. Patient characteristics are presented in Table I. Lesion characteristics are shown in Table II. Mean baseline Pd/Pa was 0.93 ±0.05. Mean cFFR value was similar to FFR value (0.83 ±0.09 vs. 0.81 ±0.09; p = 0.13) and QFR (0.81 ±0.1; p = 0.69) and iFR

Table I. Study population and procedural data (n = 44)

Age [years] 66.0 ±9.8 Male sex 32 (72.7) Height [cm] 169.8 ±8.0 Weight [kg] 79.6 ±13.5 Body mass index [kg/m²] 27.5 ±3.8 Arterial hypertension 44 (100.0) Diabetes mellitus 22 (50.0) Previous myocardial infarction 23 (52.3) Previous PCI 20 (45.5) Previous CABG 0 (0.0) Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40% 1 (2.3) Heart rate [beats/min] 71.9 ±9.5 Angina symptoms – CCS class: 1 I 38 (86.4) II 4 (9.1) III 4 (9.1) III 1 (2.3) IV 1 (2.3) <t< th=""><th>Patients</th><th>Value</th></t<>	Patients	Value
Height [cm] 169.8 ±8.0 Weight [kg] 79.6 ±13.5 Body mass index [kg/m²] 27.5 ±3.8 Arterial hypertension 44 (100.0) Diabetes mellitus 22 (50.0) Previous myocardial infarction 23 (52.3) Previous PCI 20 (45.5) Previous CABG 0 (0.0) Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Myperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Age [years]	66.0 ±9.8
Weight [kg] 79.6 ±13.5 Body mass index [kg/m²] 27.5 ±3.8 Arterial hypertension 44 (100.0) Diabetes mellitus 22 (50.0) Previous myocardial infarction 23 (52.3) Previous PCI 20 (45.5) Previous CABG 0 (0.0) Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF < 40%	Male sex	32 (72.7)
Body mass index [kg/m²] 27.5 ±3.8 Arterial hypertension 44 (100.0) Diabetes mellitus 22 (50.0) Previous myocardial infarction 23 (52.3) Previous PCI 20 (45.5) Previous CABG 0 (0.0) Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Height [cm]	169.8 ±8.0
Arterial hypertension 44 (100.0) Diabetes mellitus 22 (50.0) Previous myocardial infarction 23 (52.3) Previous PCI 20 (45.5) Previous CABG 0 (0.0) Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Weight [kg]	79.6 ±13.5
Diabetes mellitus 22 (50.0) Previous myocardial infarction 23 (52.3) Previous PCI 20 (45.5) Previous CABG 0 (0.0) Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Body mass index [kg/m²]	27.5 ±3.8
Image: symplemetric s	Arterial hypertension	44 (100.0)
Previous PCI 20 (45.5) Previous CABG 0 (0.0) Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/l] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Diabetes mellitus	22 (50.0)
Previous CABG 0 (0.0) Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF, % 52.6 ±8.5 LVEF < 40%	Previous myocardial infarction	23 (52.3)
Peripheral arterial disease 1 (2.3) Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Previous PCI	20 (45.5)
Chronic obstructive pulmonary disease 0 (0.0) Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Previous CABG	0 (0.0)
Previous stroke/TIA 0 (0.0) Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/l] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Peripheral arterial disease	1 (2.3)
Hyperlipidemia 50 (100.0) Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Chronic obstructive pulmonary disease	0 (0.0)
Smoking 16 (36.4) Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Previous stroke/TIA	0 (0.0)
Atrial fibrillation 1 (2.3) Serum creatinine [µmol/I] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Hyperlipidemia	50 (100.0)
Serum creatinine [µmol/l] 88.8 ±16.4 LVEF, % 52.6 ±8.5 LVEF < 40%	Smoking	16 (36.4)
LVEF, % 52.6 ± 8.5 LVEF < 40%	Atrial fibrillation	1 (2.3)
LVEF < 40% 1 (2.3) Heart rate [beats/min] 71.9 ±9.5 Angina symptoms – CCS class: I 6 (13.6) II 34 (77.3) III 4 (9.1) Heart failure symptoms – NYHA class: I 38 (86.4) II 4 (9.1) III 1 (2.3) IV 1 (2.3) IV 1 (2.3) Access: 30 (68.2) Femoral 14 (31.8)	Serum creatinine [µmol/l]	88.8 ±16.4
Heart rate [beats/min] 71.9 ±9.5 Angina symptoms – CCS class: 6 (13.6) II 6 (13.7) III 34 (77.3) III 4 (9.1) Heart failure symptoms – NYHA class: 38 (86.4) I 1 (2.3) IV 1 (2.3) Access: 30 (68.2) Femoral 14 (31.8)	LVEF, %	52.6 ±8.5
Angina symptoms – CCS class: I 6 (13.6) II 34 (77.3) III 4 (9.1) Heart failure symptoms – NYHA class: I 38 (86.4) II 4 (9.1) III 1 (2.3) IV 1 (2.3) Access: 30 (68.2) Femoral 14 (31.8)	LVEF < 40%	1 (2.3)
I 6 (13.6) II 34 (77.3) III 4 (9.1) Heart failure symptoms – NYHA class: 1 I 38 (86.4) II 4 (9.1) III 1 (2.3) IV 1 (2.3) Access: 30 (68.2) Femoral 14 (31.8)	Heart rate [beats/min]	71.9 ±9.5
II 34 (77.3) III 4 (9.1) Heart failure symptoms – NYHA class: 1 I 38 (86.4) II 4 (9.1) III 1 (2.3) IV 1 (2.3) Access: 30 (68.2) Femoral 14 (31.8)	Angina symptoms – CCS class:	
III 4 (9.1) Heart failure symptoms – NYHA class: 1 I 38 (86.4) II 4 (9.1) III 1 (2.3) IV 1 (2.3) Access: 30 (68.2) Femoral 14 (31.8)	I	6 (13.6)
Heart failure symptoms – NYHA class: I 38 (86.4) II 4 (9.1) III 1 (2.3) IV 1 (2.3) Access:	II	34 (77.3)
I 38 (86.4) II 4 (9.1) III 1 (2.3) IV 1 (2.3) Access: 30 (68.2) Femoral 14 (31.8)	III	4 (9.1)
II 4 (9.1) III 1 (2.3) IV 1 (2.3) Access:	Heart failure symptoms – NYHA class:	
III 1 (2.3) IV 1 (2.3) Access:	I	38 (86.4)
IV 1 (2.3) Access:	II	4 (9.1)
Access: Radial 30 (68.2) Femoral 14 (31.8)	III	1 (2.3)
Radial 30 (68.2) Femoral 14 (31.8)	IV	1 (2.3)
Femoral 14 (31.8)	Access:	
	Radial	30 (68.2)
Number of assessed vessels 3.0 (2.0–4.0)	Femoral	14 (31.8)
	Number of assessed vessels	3.0 (2.0–4.0)

Values presented as number (percentage), mean ± standard deviation or median (interquartile range). CABG – coronary artery bypass grafting, CCS – Canadian Cardiovascular Society, LVEF – left ventricle ejection fraction, NYHA – New York Heart Association, PCI – percutaneous coronary intervention, TIA – transient ischemic attack.

(0.9 ±0.07; p = 0.10, Figure 1). A total of 46 (41.8%) vessels had FFR ≤ 0.80 , 50 (45.5%) vessels had cFFR ≤ 0.83 , 44 (40.0%) vessels had QFR ≤ 0.80 , and 38 (34.5%) vessels had iFR ≤ 0.89 . Resting Pd/Pa, FFR, QFR, and iFR were strongly correlated with cFFR (Figure 2). An excellent agreement between cFFR and resting Pd/Pa (ICC 0.83, 95% CI: 0.76–0.88), FFR (ICC = 0.99, 95% CI: 0.98–0.99), QFR (ICC: 0.98, 95% CI: 0.97–0.98), and iFR (ICC = 0.88, 95% CI: 0.82–0.92) was confirmed. However, cFFR showed stronger agreement between cFFR and FFR than between cFFR and iFR in Bland-Altman analysis (Figures 3 A and B). The optimal cutoff value of cFFR was 0.83 for

Table II. Lesion characteristics (*n* = 110)

Lesions	Value
Vessel:	
LAD	43 (39.1)
Dg	9 (8.2)
Cx	28 (25.5)
Mg	9 (8.2)
RCA	21 (19.1)
Quantitative coronary angiography results:	
Lesion length [mm]	22.2 ±14.2
RVD [mm]	2.6 ±0.6
MLD [mm]	1.4 ±0.4
DS, %	44.6 ±12.0
Eccentric lesion	60 (54.5)
Moderate/severe tortuosity	44 (40.0)
Irregular contours	9 (8.2)
Moderate/severe calcifications	45 (40.9)
Ostial lesion	10 (9.1)

Values presented as number (percentage) or mean \pm standard deviation. Cx – circumflex artery, Dg – diagonal branch, DS – diameter stenosis, LAD – left anterior descending artery, Mg – marginal branch, MLD – minimal lumen diameter, RCA – right coronary artery, RVD – reference vessel diameter.




Figure 1. Mean values of resting Pd/Pa, contrast fractional flow reserve (cFFR) and fractional flow reserve (FFR), quantitative flow ratio (QFR) and instantaneous wave-free ratio (iFR)

prediction of FFR \leq 0.80 with sensitivity, specificity, and accuracy of 96.9%, 97.8%, and 97.3% respectively. 100% sensitivity was observed for a cutoff value of 0.82 and 100% specificity for a cutoff value of 0.84; AUC = 0.998 (0.995–1.00); p < 0.001, Figure 4 A). The optimal cutoff value of cFFR was 0.84 for prediction of iFR \leq 0.89 with sensitivity, specificity, and accuracy of 79.2%, 92.1%, and 83.6% respectively. 100% sensitivity was observed for a cutoff value of 0.91; AUC = 0.89 (0.83–0.95); p < 0.001 (Figure 4 B). The optimal cutoff value of baseline Pd/Pa was 0.93 for prediction of FFR \leq 0.80 with sensitivity, specificity,




Figure 2. cFFR comparisons. Correlation between resting Pd/Pa (**A**), fractional flow reserve (FFR, **B**), quantitative flow ration (QFR, **C**) instantaneous wave-free ratio (iFR, **D**) and contrast fractional flow reserve (cFFR)

and accuracy of 92.2%, 80.4%, and 87.3% respectively. 100% sensitivity was observed for a cutoff value of 0.85 and 100% specificity for a cutoff value of 0.98; AUC = 0.92 (0.87–0.97); p < 0.001. The optimal cutoff value of baseline Pd/Pa was 0.93 for prediction of iFR \leq 0.89 with sensitivity, specificity, and accuracy of 91.7%, 94.7%, and 92.7% respectively. 100% sensitivity was observed for a cutoff value of 0.91 and 100% specificity for a cutoff value of 0.97; AUC = 0.98 (0.95–1.00); p < 0.001.

Discussion

The results of our study showed that cFFR, calculated as Pd/Pa after the induction of submaximal hyperemia using the intracoronary bolus of standard radiographic contrast dye, may be accurate in predicting FFR values of borderline coronary lesions. Moreover, cFFR is able to predict the iFR values in assessing intermediate coronary stenosis. Most interestingly, we found a significant correlation of cFFR with a novel index – QFR – which is calculated based on 3D-QCA and corrected TIMI frame count algorithms. Our results suggest that the use of the cut-off value of 0.82 for cFFR could be a reasonable option in patients who have contraindications to the administration of adenosine, or the assessment of iFR is not possible in the cathlab.

Despite its demonstrated value in guiding coronary revascularization, the rate of adoption of FFR in real-world clinical practice remains rather low [3]. FFR assessment requires maximal hyperemia induced by a vasoactive agent such as adenosine, which may cause some adverse effects during infusion or intracoronary injection (e.g. complete atrioventricular block, chest pain, dyspnea).




Figure 3. Bland-Altman plots for the agreement between contrast fractional flow reserve (cFFR) and fractional flow reserve (FFR, **A**) and instantaneous wave-free ratio (iFR, **B**)




Figure 4. Receiver operating characteristic curve calculated using the threshold cut-off value of contrast fractional flow reserve (cFFR) for fractional flow reserve (FFR) of \leq 0.80 (**A**) and instantaneous wave-free ratio (iFR) \leq 0.89 (**B**)

Also, adenosine is still quite expensive. Furthermore, to overcome financial difficulties or side effects associated with the use of adenosine, a new adenosine free index based on measurement of the resting gradient called iFR was introduced. Importantly, iFR has been shown as non-inferior to FFR in terms of lesion severity assessment along with long-term clinical outcomes [7, 8]. Pd/Pa ratio registered by pressure wire during submaximal reactive hyperemia after an intracoronary bolus of contrast medium may be sufficient for evaluation of the physiological significance of stenosis, avoiding the need of adenosine administration. In the RINASCI study, a strong correlation between cFFR and FFR values was observed (r = 0.94) with a close agreement at Bland-Altman analysis (95% CI of disagreement: -0.029 to 0.072). ROC curve analysis showed excellent accuracy of the cFFR cut-off of ≤ 0.83 in predicting an FFR value ≤ 0.80 (AUC 0.97 (95% CI: 0.91– 0.99, specificity 96.1%, sensitivity 85.7%)) [20]. In our study, two lesions had a cFFR value of 0.82 and another two lesions had a value of 0.83, but when assessed with

FFR, the lesions were classified as non-significant (FFR value 0.83 and 0.84, respectively). On the other hand, in our study cFFR \geq 0.88 also predicted negative FFR values (> 0.8). In the MEMENTO-FFR study, resting Pd/Pa and cFFR were significantly higher than FFR (0.93 ±0.05 vs. 0.87 ±0.08 vs. 0.84 ±0.08, respectively; *p* < 0.001) [21]. A strong correlation and a good agreement in Bland-Altman analysis between cFFR and FFR were observed (r =0.90; and 95% CI of disagreement: from -0.042 to 0.11) [20]. ROC curve analysis showed excellent accuracy (89%) of the cFFR cut-off of \leq 0.85 in predicting an FFR value ≤ 0.80 (AUC 0.95 (95% CI: 0.94–0.96)), significantly better than that observed using resting Pd/Pa (AUC = 0.90, 95% CI: 0.88–0.91; *p* < 0.001) [21]. In a study by Topcu et al. cFFR correlated well with FFR (r = 0.89) and showed good agreement in Bland-Altman analysis (mean bias was 0.027, 95% limits for agreement from -0.038 to 0.092) [22]. The CONTRAST study [12] compared the ability of cFFR vs. resting Pd/Pa and iFR to predict FFR. The results showed that cFFR was superior to resting Pd/Pa and iFR in predicting FFR while iFR and resting Pd/Pa provided equivalent diagnostic accuracy. In our study, the results clearly confirm that cFFR correlated strongly with FFR and OFR values. cFFR's correlation with iFR was weaker, but still significant. In practice, it means that without the use of adenosine or any other hyperemic agent but using cFFR, a physician has a simple and always available tool to evaluate the functional significance of coronary stenosis, much better than that which we can obtain using resting Pd/Pa. Moreover, iFR assessment is not available in every cathlab worldwide. QFR showed a strong prediction ability of FFR and iFR in previous studies [9, 10, 18, 23-26]. However, QFR is assessed offline in the majority of cases and requires some time for evaluation. In a study by Sejr-Hansen et al., the authors compared online and offline QFR in patients presenting with acute coronary syndromes, yielding similar results and good diagnostic performance with staged FFR as a reference, and a moderate diagnostic performance with staged iFR [27]. In our study, surprisingly, cFFR correlated well with QFR, even more strongly than with iFR, even though QFR and iFR are both non-hyperemic methods. However, this aspect requires further investigation, as no more data so far are available.

Our study has several limitations. First, the most important limitation was the small sample size. Second, while assessing cFFR, 3 ml of contrast medium was administered manually instead of automatically. However, manual administration is more common in daily practice.

Conclusions

Contrast medium Pd/Pa ratio seems to be accurate in predicting the functional significance of coronary stenosis assessed with FFR, iFR, and QFR. The optimal cutoff value of cFFR was 0.83 for prediction of FFR \leq 0.80 and 0.84 – for iFR \leq 0.89.

Acknowledgments

The study was supported by a grant from the Jagiellonian University Medical College (K/ZDS/005469).

Conflict of interest

The authors declare no conflict of interest.

References

- Bech GJ, De Bruyne B, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation 2001; 103: 2928-34.
- Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007; 49: 2105-11.
- 3. Tonino PA, De Bruyne B, Pijls NH, et al.; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360: 213-24.
- De Bruyne B, Pijls NH, Kalesan B, et al.; FAME 2 Trial Investigators. Fractional flow reserveguided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012; 367: 991-1001.
- 5. Kleiman NS. Bringing it all together: integration of physiology with anatomy during cardiac catheterization. J Am Coll Cardiol 2011; 58: 1219-21.
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al.; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165.
- 7. Davies JE, Sen S, Dehbi HM, et al. Use of the Instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 2017; 376: 1824-34.
- Götberg M, Christiansen EH, Gudmundsdottir IJ, et al.; iFR-SWE-DEHEART Investigators. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 2017; 376: 1813-23.
- 9. Tu S, Westra J, Yang J, et al. Diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: the International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv 2016; 9: 2024-35.
- Kleczyński P, Dziewierz A, Rzeszutko L, et al. Is quantitative flow ratio enough to accurately assess intermediate coronary stenosis? A comparison study with fractional flow reserve. Cardiol J 2019; 26: 793-5.
- 11. Baile EM, Paré PD, D'yachkova Y, Carere RG. Effect of contrast media on coronary vascular resistance: contrast-induced coronary vasodilation. Chest 1999; 116: 1039-45.
- Johnson NP, Jeremias A, Zimmermann FM, et al. Continuum of vasodilator stress from rest to contrast medium to adenosine hyperemia for fractional flow reserve assessment. JACC Cardiovasc Interv 2016; 9: 757-67.
- 13. Topcu S, Tanboğa IH, Aksakal E, et al. Efficacy of coronary fractional flow reserve using contrast medium compared to adenosine. Adv Interv Cardiol 2016; 12: 212-6.
- 14. Shiode N, Okimoto T, Tamekiyo H, et al. Contrast-induced hyperemia as an alternative to drug-induced hyperemia in the eval-

uation of the fractional flow reserve in coronary lesions. Intern Med 2017; 56: 253-7.

- Sen S, Escaned J, Malik IS, et al. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) Study. J Am Coll Cardiol 2012; 59: 1392-402.
- 16. Legutko J, Kleczyński P, Dziewierz A, et al. Comparison of hyperemic efficacy between femoral and antecubital fossa vein adenosine infusion for fractional flow reserve assessment. Adv Interv Cardiol 2019; 15: 52-8.
- 17. Legutko J, Kleczyński P, Dziewierz A, et al. Adenosine intracoronary bolus dose escalation versus intravenous infusion to induce maximum coronary hyperemia for fractional flow reserve assessment. Kardiol Pol 2019; 77: 610-7.
- 18. Kleczyński P, Dziewierz A, Rzeszutko Ł, et al. Borderline coronary lesion assessment with quantitative flow ratio and its relation to the instantaneous wave-free ratio. Adv Med Sci 2020; 66: 1-5.
- 19. Tu S, Barbato E, Koszegi Z, et al. Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI frame count: a fast computer model to quantify the functional significance of moderately obstructed coronary arteries. JACC Cardiovasc Interv 2014; 7: 768-77.
- 20. Leone AM, Scalone G, De Maria GL, et al. Efficacy of contrast medium induced Pd/Pa ratio in predicting functional significance of intermediate coronary artery stenosis assessed by fractional flow reserve: insights from the RINASCI study. EuroIntervention 2015; 11: 421-7.
- Leone AM, Martin-Reyes R, Baptista SB, et al. The Multi-center Evaluation of the Accuracy of the Contrast MEdium INduced Pd/ Pa RaTiO in Predicting FFR (MEMENTO-FFR) Study. EuroIntervention 2016; 12: 708-15.
- 22. Topcu S, Tanboğa IH, Aksakal E, et al. Efficacy of coronary fractional flow reserve using contrast medium compared to adenosine. Adv Interv Cardiol 2016; 12: 212-6.
- 23. Emori H, Kubo T, Kameyama T, et al. Quantitative flow ratio and instantaneous wave-free ratio for the assessment of the functional severity of intermediate coronary artery stenosis. Coron Artery Dis 2018; 29: 611-7.
- 24. Hwang D, Choi KH, Lee JM, et al. Diagnostic agreement of quantitative flow ratio with fractional flow reserve and instantaneous wave-free ratio. J Am Heart Assoc 2019; 8: e011605.
- 25. Zuo W, Yang M, Chen Y, et al. Meta-analysis of diagnostic performance of instantaneous wave-free ratio versus quantitative flow ratio for detecting the functional significance of coronary stenosis. Biomed Res Int 2019; 2019: 5828931.
- 26. Watarai M, Otsuka M, Yazaki K, et al. Applicability of quantitative flow ratio for rapid evaluation of intermediate coronary stenosis: comparison with instantaneous wave-free ratio in clinical practice. Int J Cardiovasc Imaging 2019; 35: 1963-9.
- Sejr-Hansen M, Westra J, Thim T, et al. Quantitative flow ratio for immediate assessment of nonculprit lesions in patients with ST-segment elevation myocardial infarction – an iSTEMI substudy. Catheter Cardiovasc Interv 2019; 94: 686-92.